Literature DB >> 17276437

Assessment of gonadotropin therapy in male hypogonadotropic hypogonadism.

Tomomoto Ishikawa1, Takeshi Ooba, Yutaka Kondo, Kohei Yamaguchi, Masato Fujisawa.   

Abstract

The objective of this study was to determine the efficacy of gonadotropin therapy in men with hypogonadotropic hypogonadism. Gonadotropin therapy is a safe and effective therapy for hypogonadotropic hypogonadism.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17276437     DOI： 10.1016/j.fertnstert.2006.11.022

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  10 in total

1.  Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy.

Authors:  Taylor P Kohn; Matthew R Louis; Stephen M Pickett; Mark C Lindgren; Jaden R Kohn; Alexander W Pastuszak; Larry I Lipshultz
Journal:  Fertil Steril       Date:  2016-11-14       Impact factor: 7.329

2.  Efficacy and Safety of Human Chorionic Gonadotropin Monotherapy for Men With Hypogonadal Symptoms and Normal Testosterone.

Authors:  Isaac Zucker; Quinn Rainer; Raghav K Pai; Ranjith Ramasamy; Thomas A Masterson
Journal:  Cureus       Date:  2022-05-31

Review 3.  Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS).

Authors:  Ankit Desai; Musaab Yassin; Axel Cayetano; Tharu Tharakan; Channa N Jayasena; Suks Minhas
Journal:  Ther Adv Urol       Date:  2022-06-26

4.  Outcome of gonadotropin therapy for male infertility due to hypogonadotrophic hypogonadism.

Authors:  Rafif Farhat; Fatma Al-zidjali; Ali S Alzahrani
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

Review 5.  Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use.

Authors:  J Abram McBride; Robert M Coward
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285

6.  The effectiveness of zinc supplementation in men with isolated hypogonadotropic hypogonadism.

Authors:  Yan-Ling Liu; Man-Na Zhang; Guo-Yu Tong; Shou-Yue Sun; Yan-Hua Zhu; Ying Cao; Jie Zhang; Hong Huang; Ben Niu; Hong Li; Qing-Hua Guo; Yan Gao; Da-Long Zhu; Xiao-Ying Li
Journal:  Asian J Androl       Date:  2017 May-Jun       Impact factor: 3.285

7.  The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men.

Authors:  Luyao Zhang; Ke Cai; Yu Wang; Wen Ji; Zhen Cheng; Guanming Chen; Zhihong Liao
Journal:  Am J Mens Health       Date:  2018-12-20

8.  Evaluation of gonadotropin-replacement therapy in male patients with hypogonadotropic hypogonadism.

Authors:  Mazhar Ortac; Muhammed Hidir; Emre Salabas; Abubekir Boyuk; Caner Bese; Yasar Pazir; Ates Kadioglu
Journal:  Asian J Androl       Date:  2019 Nov-Dec       Impact factor: 3.285

9.  Testosterone versus hCG in Hypogonadotropic Hypogonadism - Comparing Clinical Effects and Evaluating Current Practice.

Authors:  Swashti Agarwal; Duong D Tu; Paul F Austin; Michael E Scheurer; Lefkothea P Karaviti
Journal:  Glob Pediatr Health       Date:  2020-09-23

10.  Efficacy and Outcome Predictors of Gonadotropin Treatment for Male Congenital Hypogonadotropic Hypogonadism: A Retrospective Study of 223 Patients.

Authors:  Zhaoxiang Liu; Jangfeng Mao; Xueyan Wu; Hongli Xu; Xi Wang; Bingkun Huang; Junjie Zheng; Min Nie; Hongbing Zhang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.